Valuation: Abivax

Capitalization 798.54Cr 933.96Cr 741.27Cr 695.2Cr 1.29TCr 86TCr 1.38TCr 8.51TCr 3.37TCr 40TCr 3.5TCr 3.43TCr 1,47700Cr P/E ratio 2025 *
-29.2x
P/E ratio 2026 * -36.9x
Enterprise value 744.65Cr 870.94Cr 691.25Cr 648.29Cr 1.2TCr 80TCr 1.29TCr 7.93TCr 3.14TCr 38TCr 3.27TCr 3.2TCr 1,37700Cr EV / Sales 2025 *
1,298x
EV / Sales 2026 * 208x
Free-Float
90.83%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.36%
1 week-3.70%
Current month-13.62%
1 month-9.88%
3 months+30.65%
6 months+1,054.27%
Current year-13.62%
More quotes
1 week 98.6
Extreme 98.6
116.4
1 month 94.2
Extreme 94.2
132
Current year 94.2
Extreme 94.2
132
1 year 4.51
Extreme 4.51
132
3 years 4.51
Extreme 4.51
132
5 years 4.51
Extreme 4.51
132
10 years 3.87
Extreme 3.87
132
More quotes
Manager TitleAgeSince
Chief Executive Officer 67 05/05/2023
Director of Finance/CFO - 02/01/2017
Chief Tech/Sci/R&D Officer 59 15/07/2024
Director TitleAgeSince
Chairman - 16/08/2022
Director/Board Member - -
Chairman 67 05/05/2023
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.36%-3.70%+1,577.42%+1,385.71% 933.96Cr
-0.39%-0.50%-2.63%+12.16% 4.93TCr
-0.25%-0.03%+17.42%+5.44% 4.11TCr
-0.92%+0.09%+52.38%+25.88% 3.78TCr
-1.45%-7.69%+17.41%+37.09% 3.05TCr
+0.66%-4.40%+187.98%+328.82% 2.27TCr
-0.79%-0.56%+78.05%+156.59% 1.75TCr
Average -0.18%-1.72%+275.43%+278.81% 2.98TCr
Weighted average by Cap. -0.34%-1.24%+112.67%+125.24%
See all sector performances

Financials

2025 *2026 *
Net sales 57.36L 67.08L 53.24L 49.93L 92.64L 61Cr 99.2L 6.11Cr 2.42Cr 29Cr 2.52Cr 2.46Cr 106.08Cr 3.58Cr 4.19Cr 3.33Cr 3.12Cr 5.79Cr 383.88Cr 6.2Cr 38Cr 15Cr 181.43Cr 16Cr 15Cr 662.73Cr
Net income -26Cr -31Cr -24Cr -23Cr -42Cr -2.82TCr -45Cr -280.16Cr -110.86Cr -1.33TCr -115.34Cr -112.98Cr -4.86TCr -19Cr -23Cr -18Cr -17Cr -31Cr -2.07TCr -33Cr -205.59Cr -81Cr -977.11Cr -85Cr -83Cr -3.57TCr
Net Debt -54Cr -63Cr -50Cr -47Cr -87Cr -5.77TCr -93Cr -574.03Cr -227.16Cr -2.73TCr -236.33Cr -231.49Cr -9.97TCr -54Cr -63Cr -50Cr -47Cr -88Cr -5.81TCr -94Cr -577.45Cr -228.51Cr -2.74TCr -237.73Cr -232.87Cr -10TCr
More financial data * Estimated data
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
67
More about the company
Date Price Change Volume
22/26/22 104.00 +1.36% 1,25,180
21/26/21 102.60 -1.16% 1,85,808
20/26/20 103.80 +2.77% 3,80,689
19/26/19 101.00 -1.17% 73,180
16/26/16 102.20 -1.35% 1,42,921

Real-time Euronext Paris, January 22, 2026 at 10:05 pm IST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
102.60EUR
Average target price
109.03EUR
Spread / Average Target
+6.27%
Consensus

Quarterly revenue - Rate of surprise